For the year ending 2025-12-31, RXO had -$17M decrease in cash & cash equivalents over the period. -$8M in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -100 |
| Depreciation and amortization expense | 116 |
| Stock compensation expense | 29 |
| Deferred tax benefit | -21 |
| Deemed non-pro rata distribution | 0 |
| Impairment of operating lease assets | 4 |
| Goodwill impairment | 12 |
| Other | -11 |
| Accounts receivable | 5 |
| Other current assets and other long-term assets | -19 |
| Accounts payable | -16 |
| Accrued expenses, other current liabilities and other long-term liabilities | 2 |
| Net cash provided by (used in) operating activities | 51 |
| Payment for purchases of property and equipment | 59 |
| Business acquisition, net of cash acquired | 10 |
| Proceeds from sale of property and equipment | 2 |
| Other | 4 |
| Net cash used in investing activities | -71 |
| Proceeds from borrowings on revolving credit facilities | 566 |
| Repayment of borrowings on revolving credit facilities | 533 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 |
| Payment for equity issuance costs | 1 |
| Repayment of debt and finance leases | 2 |
| Payment for debt issuance costs | 0 |
| Payment for tax withholdings related to vesting of stock compensation awards | 19 |
| Repurchase of common stock | 0 |
| Other | -10 |
| Net cash provided by (used in) financing activities | 1 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 2 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -17 |
| Cash and cash equivalents at beginning of period | 35 |
| Cash and cash equivalents at end of period | 18 |
RXO, Inc. (RXO)
RXO, Inc. (RXO)